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The ﬁrst three authors contributed equally to this article, and all
should be considered ﬁrst authorRapid surveillance of inﬂuenza infections and assessing the po-
tential risks is important for inﬂuenza pandemic preparedness.
However, the current polymerase chain reaction (PCR)-based
standard protocol for rapid inﬂuenza subtyping in clinics may
fail because of hypermutations of inﬂuenza viruses. The ultimateMicrobiol Infect 2015; 21: 290.e1–290.e4
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.10.016subtyping relies on full genome sequencing after laboratory
culture of inﬂuenza viruses in chicken eggs or mammalian cells.
Because laboratory culture of inﬂuenza viruses requires sufﬁ-
cient biosecurity levels, the ﬁnal subtyping may be delayed for
days to weeks. Next-generation sequencing (NGS) technologies
have been successfully applied to obtain full genomes of newly
emergent inﬂuenza A viruses directly from clinical samples
[1–3] and do not require high biosafety qualiﬁcations. Hence, it
is promising to equip NGS technologies in hospitals to greatly
improve the speed and quality of clinical inﬂuenza surveillance.
Currently many benchtop NGS instruments are available,
such as Ion Torrent PGM (Life Technologies), 454 GS Junior
(Roche) and MiSeq (Illumina). However, their performance for
inﬂuenza surveillance has not been strictly evaluated on real
clinical samples. We evaluated the performance of Ion Torrent
PGM and MiSeq on two real clinical samples infected with
inﬂuenza A (H7N9) and (H10N8) viruses, respectively, and
found that both instruments can correctly determine the sub-
types, obtain nearly full genomes and reveal potential poly-
morphisms. MiSeq had slightly fewer sequence conﬂicts to the
reference genomes and slightly larger genome coverage
compared with Ion Torrent PGM. Both technologies require
nucleic acids at the nanogram level without the need for
inﬂuenza culture, and can generate results within 1 day.
We collected sputum specimens from two patients,
respectively infected by inﬂuenza A (H7N9) and (H10N8) vi-
ruses [1, 2]. Total RNAs were extracted and ampliﬁed by
sequence-independent PCR for each specimen [4], then divided
into two pieces and subject to sequencing with Ion Torrent
PGM and MiSeq, respectively. For the H7N9 specimen, low
sequencing depth was applied and 2 900 928 Ion Torrent PGM
reads with average 175 bps length and 30 612 165 MiSeq reads
with 80 bps length were obtained. For the H10N8 specimen,
high sequencing depth was applied, and 6 159 868 Ion Torrent
PGM reads with average 212 bps length and 69 663 375 MiSeq
reads with 100 bps length were obtained.
We ﬁrst aligned the sequencing reads to the National Center
for Biotechnology Information (NCBI) nonredundant nucleo-
tide database by BLASTN software (version 2.2.22) [5] to
examine the taxonomic composition of the specimens. We
found that the read-level alignment to databases can success-
fully determine the subtypes of the inﬂuenza A viruses. Upon
the revealed subtypes, we selected those complete genomic
sequences that demonstrated the highest identities to the reads
as references. Then we aligned those reads to the reference
sequences by the Bowtie2 software (version 2.2.3) [6] and
obtained the consensus genomic sequences and single nucleo-
tide polymorphism (SNP) sites for each virus by SAMtools
(version 0.1.19) [7]. The assembled genome sequences haveious Diseases. Published by Elsevier Ltd. All rights reserved
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numbers KM392384 through KM392415.
We compared the consensus genomic sequences to the
genomic sequences obtained by Sanger sequencing [1,2] and
found that both technologies revealed nearly full genomes of
inﬂuenza A (H7N9) and (H10N8) viruses. For the H7N9 virus,
Ion Torrent PGM resolved 97.9% of the whole genomewith only
two base conﬂicts (error rate <0.02%) andMiSeq resolved 98.1%
with only one base conﬂict (error rate <0.01%). For the H10N8TABLE 1. Comparison of consensus genomic sequences of Ion To
H7N9 virus
Segment Position Sanger
PB2 1–5 ATGGA
PB2 73–74 GT
PB2 87–92 CATAAT
PB2 107 C
PB2 192 G
PB2 967 T
PB2 1601 C
PB2 2280 A
PB1 1–9 ATGGATGTC
PB1 21 A
PB1 34 G
PB1 44–45 AA
PB1 303 G
PA 1–14 ATGGAAGACTTTGT
PA 15–35 GCGACAGTGCTTCAATCCAAT
PA 36–42 GATCGTC
PA 43–44 GA
PA 1136 T
PA 1899 C
PA 2074 G
PA 2115 G
PA 2119 G
PA 2134–2150 ACACATGCACTAAGATA
PA 2151 G
HA 1–2 AT
HA 11 A
HA 193 A
HA 1501 T
HA 1596 A
HA 1678–1681 ATAT
HA 1682–1683 AA
NP 1–7 ATGGCGT
NP 540 T
NP 715 A
NP 886 T
NP 1305 T
NP 1492–1497 AATTGA
NA 1–12 ATGAATCCAAAT
NA 1392–1395 CCTC
NA 1396–1398 TAA
MP 1–5 ATGAG
MP 6–9 TCTT
MP 17 A
MP 25 A
MP 193 A
MP 343 G
MP 945–986 TGACGATGGTCATTTTGTCAACATAGAGCTGA
MP 987 A
NS 1–4 ATGG
NS 291 A
NS 425 A
NS 659 G
NS 696–698 AAA
NS 716–728 GAAGTACGACATA
NS 741–754 CGGAGAATAGCTTT
NS 769 T
NS 812–816 AGAAC
NS 817–822 TTTCTC
NS 823–832 GTTTCAGCTT
NS 833–838 ATTTAA
PCR, polymerase chain reaction; PB, polymerase basic; PA, polymerase acidic; HA, hemagglu
nonstructural protein; av, available; na, not available; syn, synonymous substitution without a
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Invirus, Ion Torrent PGM resolved 99.8% of the whole genome
with only two base conﬂicts (error rate <0.03%) and MiSeq
resolved 99.9% with only one base conﬂict (error rate <0.01%).
The missing genomic sequences were located at the ends of the
genomic segments and were probably caused by library prepa-
ration biases. The genomic coverage of Ion Torrent PGM was
~122-fold for H7N9 and ~12 930– fold for H10N8, and that of
MiSeq was ~75-fold for H7N9 and ~15 178– fold for H10N8.
With the coverage for H10N8 increased ~100-fold compared torrent PGM and MiSeq with Sanger sequencing of inﬂuenza A
MiSeq
Ion Torrent
PGM
Amino acid
change
PCR
conﬁrmation
av na
av na
av na
C na
R G M64I
Y Y F323L
Y C F534S Yes
A na
na av
na A
G na
av na
R G syn Yes
na na
av na
na na
av na
K K V379G
Y Y syn
K K E692stop
K T syn Yes
K T V707F Yes
av na
na na
av na
na A
A R M65V
Y T Y501H
G A syn
na av
na na
av na
na T
R A M272V
K T Y296D
K T syn
Av na
Av na
na av
na na
na na
av na
M A E6A
R A T9A
M A T65P
R G V115I
AGTA na av
na na
av na
R A syn
R A E142G
G na
av na
av na
av na
T na
av na
na na
na av
na na
tinin; NP, nucleocapsid protein; NA, neuraminidase; MP, matrix protein; NS,
mino acid change.
fectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 290.e1–290.e4
TABLE 2. Comparison of consensus genomic sequences of Ion Torrent PGM and MiSeq with Sanger sequencing of inﬂuenza A
H10N8 virus
Segment Position Sanger MiSeq Ion Torrent PGM Amino acid change
PCR
conﬁrmation
PB2 4 G K G E2stop
PB2 875 T K T V292G
PB2 884 T K T V295G
PB2 2081 T T W F697Y
PB1 2276 A A M E751A
PB1 2340–2341 CT av na
PA 2 T W C M1K/M1T
PA 570 C M M syn
HA 1430 G G R C477Y
HA 1435 G G S E479Q
NP 3 G S G M1I
NP 4 G G R A2T
NP 59 A A R Q20R
NP 62 A A R N21S
NP 63 T T Y N21S
NP 64 G G K A22S
NP 69 T T W Syn
NP 72 G G K E24D
NP 1391 T T K F464C
MP 4 A A T noncoding
MP 937 A A R syn
MP 943 G G K syn
MP 1020 T na T
MP 1021–1026 TTCTAC na na
NS 3 A A C noncoding
NS 641 G R G E208K Yes
NS 834 A A G N272S
NS 875–883 GTTTCTACT av na
PCR, polymerase chain reaction; PB, polymerase basic; PA, polymerase acidic; HA, hemagglutinin; NP, nucleocapsid protein; NA, neuraminidase; MP, matrix protein; NS,
nonstructural protein; av, available; na, not available; syn, synonymous substitution without amino acid change.
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quences also increased, but the increases were limited.
For H7N9, Ion Torrent PGM revealed ﬁve potential SNPs
and MiSeq revealed 19 potential SNPs (Table 1), of which four
were identiﬁed by both technologies. Another four MiSeq SNPs
were conﬁrmed by PCR. For H10N8, Ion Torrent PGM
revealed 15 potential SNPs and MiSeq revealed seven potential
SNPs (Table 2), one of which was identiﬁed by both technol-
ogies. Another single MiSeq SNP was conﬁrmed by PCR. Most
of the potential SNPs caused amino acid changes.
Upon the consensus genomic sequences and the potential
SNPs revealed by both the technologies, we checked the muta-
tion hot spots of inﬂuenza viruses that are tightly related to host
adaptations and drug resistance. Both technologies revealed E at
the 627 position of the PB2 segment and I at the 368 position of
the PB1 segment for H7N9. Becausemutations E627K in PB2 and
I368V in PB1 are closely associated with virulence and trans-
missibility of avian inﬂuenza A virus inmammals [8–10], the E and
I in H7N9 suggest its avian origin. For H10N8, the 627 position of
PB2 was K and the 368 position of PB1 was V, which may imply
high virulence for the virus. S31Nwas observed inmatrix protein
for both H7N9 and H10N8, which may suggest that the viruses
were resistant to amantadine [11]. No mutations related to
neuraminidase inhibitors were found for both viruses, suggesting
that oseltamivir and other neuraminidase inhibitor drugs may be
effective to inhibit the viruses [12].Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectWe compared the performance of two NGS instruments for
determination of the full genomes of newly emergent inﬂuenza
A viruses directly from small clinical specimens. We found that
both instruments can rapidly generate results within 1 day,
accurately identify the subtypes, assemble nearly full genomes
and reveal potential polymorphisms; MiSeq had a slightly lower
error rate and covered slightly more genomic regions. Close
investigation of the genomic sequences provided important
information about the disease’s possible origin, virulence and
drug resistance. Because these NGS technologies do not
require high biosafety levels, it is expected that equipment of
NGS technologies in hospitals will greatly improve the speed
and quality of inﬂuenza surveillance.Transparency declarationThis study was ﬁnancially supported by projects from National
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